Oncology Institute - CW22 | 10-Q: FY2025 Q3 Revenue: USD 136.56 M

Revenue: As of FY2025 Q3, the actual value is USD 136.56 M.

EPS: As of FY2025 Q3, the actual value is USD -0.14.

EBIT: As of FY2025 Q3, the actual value is USD -6.134 M.

Patient Services

• Revenue: $60,195 for the three months ended September 30, 2025, compared to $49,752 for the same period in 2024, representing a 21.0% increase. For the nine months ended September 30, 2025, revenue was $169,154 compared to $154,666 in 2024, a 9.4% increase.
• Direct Costs: $54,572 for the three months ended September 30, 2025, compared to $45,118 for the same period in 2024, a 21.0% increase. For the nine months ended September 30, 2025, direct costs were $152,802 compared to $141,137 in 2024, an 8.3% increase.

Dispensary

• Revenue: $75,895 for the three months ended September 30, 2025, compared to $48,210 for the same period in 2024, a 57.4% increase. For the nine months ended September 30, 2025, revenue was $187,761 compared to $132,329 in 2024, a 41.9% increase.
• Direct Costs: $63,072 for the three months ended September 30, 2025, compared to $40,091 for the same period in 2024, a 57.3% increase. For the nine months ended September 30, 2025, direct costs were $154,021 compared to $111,701 in 2024, a 37.9% increase.

Clinical Trials & Other

• Revenue: $474 for the three months ended September 30, 2025, compared to $1,939 for the same period in 2024, a 75.6% decrease. For the nine months ended September 30, 2025, revenue was $3,857 compared to $6,150 in 2024, a 37.3% decrease.
• Direct Costs: $0 for the three months ended September 30, 2025, compared to $326 for the same period in 2024. For the nine months ended September 30, 2025, direct costs were $279 compared to $946 in 2024, a 70.5% decrease.

Cash Flow

• Operating Cash Flow: Net cash used in operating activities was $27,820 for the nine months ended September 30, 2025, compared to $30,724 for the same period in 2024.
• Investing Cash Flow: Net cash used in investing activities was $2,014 for the nine months ended September 30, 2025, compared to net cash provided of $47,966 for the same period in 2024.
• Financing Cash Flow: Net cash provided by financing activities was $7,823 for the nine months ended September 30, 2025, compared to net cash used of $3,328 for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: The company has implemented initiatives to reduce costs and more effectively manage working capital, resulting in a 5% reduction in SG&A expenses compared to the prior year same quarter.
• Non-Core Business: The Clinical Trials segment is operated by a third party under a profit-sharing arrangement, which resulted in a write-off of the segment’s net assets for the nine months ended September 30, 2025.